Treatment characteristics
| Characteristic . | Salvage cohort (n = 54) . | Bridging cohort (n = 51) . | P value . |
|---|---|---|---|
| Pola treatment | |||
| Chemotherapy backbone | .6 (chemotherapy backbone vs no chemotherapy backbone) | ||
| pola-BR | 32 (59.3%) | 27 (52.9%) | |
| pola-B | 1 (1.85%) | 1 (1.96%) | |
| pola-R-CHP | 0 | 1 (1.96%) | |
| pola-R-gemcitabine | 1 (1.85%) | 0 | |
| No chemotherapy backbone | |||
| pola-R | 20 (37.0%) | 19 (37.3%) | |
| pola-monotherapy | 0 | 3 (5.9%) | |
| Median number of pola cycles (range) | 4 (1-9) | 2 (1-6) | .001 |
| Reason for treatment cessation | |||
| Treatment completed with 6 cycles | 22 (40.7%) | 4 (7.8%) | |
| Availability of intended IT | n/a | 23 (45.1%) | |
| Progressive disease | 28 (51.8%) | 21 (41.2%) | |
| AEs | 2 (3.7%) | 0 | |
| Withdrawal of patients | 1 (1.9%) | 0 | |
| Unknown | 1 (1.9%) | 3 (5.9%) |
| Characteristic . | Salvage cohort (n = 54) . | Bridging cohort (n = 51) . | P value . |
|---|---|---|---|
| Pola treatment | |||
| Chemotherapy backbone | .6 (chemotherapy backbone vs no chemotherapy backbone) | ||
| pola-BR | 32 (59.3%) | 27 (52.9%) | |
| pola-B | 1 (1.85%) | 1 (1.96%) | |
| pola-R-CHP | 0 | 1 (1.96%) | |
| pola-R-gemcitabine | 1 (1.85%) | 0 | |
| No chemotherapy backbone | |||
| pola-R | 20 (37.0%) | 19 (37.3%) | |
| pola-monotherapy | 0 | 3 (5.9%) | |
| Median number of pola cycles (range) | 4 (1-9) | 2 (1-6) | .001 |
| Reason for treatment cessation | |||
| Treatment completed with 6 cycles | 22 (40.7%) | 4 (7.8%) | |
| Availability of intended IT | n/a | 23 (45.1%) | |
| Progressive disease | 28 (51.8%) | 21 (41.2%) | |
| AEs | 2 (3.7%) | 0 | |
| Withdrawal of patients | 1 (1.9%) | 0 | |
| Unknown | 1 (1.9%) | 3 (5.9%) |
AEs, adverse events; IT, immunotherapy.